Skip to content
LATEST
Health

Drug-Resistant Infections Surge Across European Hospitals

European hospitals report a 72% surge in drug-resistant Klebsiella pneumoniae infections, missing 2030 health targets and highlighting the limitations of…

Drug-Resistant Infections Surge Across European Hospitals

European healthcare systems are facing a significant increase in antimicrobial resistance, characterized by a 72% rise in bloodstream infections caused by drug-resistant Klebsiella pneumoniae between 2019 and 2025. This trend significantly exceeds established public health targets, which aimed for a 5% reduction in these infections by 2030. Mortality rates for these specific infections range between 40% and 70%, presenting a critical challenge to hospital safety and patient outcomes.

Data indicates that several strains of the bacterium have developed resistance to nearly all available antibiotics, including newly developed treatments. While infection control measures have successfully reduced rates of MRSA by 19% since 2019, these protocols have proven insufficient against Klebsiella pneumoniae. Experts attribute this to the bacterium's ability to persist in human reservoirs, necessitating more rigorous hygiene and environmental disinfection standards than those currently applied in many clinical settings.

Furthermore

Broader antimicrobial resistance trends remain concerning, with E. coli infections increasing by 16.4% over the same period, missing the 10% reduction target. Furthermore, total antibiotic consumption in the EU declined by only 5%, falling well short of the 20% reduction goal set for 2030. While the proportion of appropriate antibiotic usage has reached 62.5%, the overall pace of improvement remains behind schedule.

Legislative efforts are underway to address these systemic risks, with new pharmaceutical regulations expected in December. These measures aim to incentivize the development of new antibiotics through market exclusivity and structured procurement models. Health authorities are increasingly prioritizing genomic surveillance to improve the speed of transmission detection and to better inform clinical treatment decisions in high-risk hospital environments.

More stories

Latest news